[
    [
        {
            "time": "2021-11-28",
            "original_text": "凯莱英子公司获签27.2亿元供货大单",
            "features": {
                "keywords": [
                    "凯莱英",
                    "子公司",
                    "供货大单",
                    "27.2亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "凯莱英子公司获签27.2亿元供货大单",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "深桑达A拟投资数字广东公司；凯莱英子公司签27.2亿元供货大单",
            "features": {
                "keywords": [
                    "深桑达A",
                    "数字广东",
                    "凯莱英",
                    "子公司",
                    "供货大单",
                    "27.2亿元"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "信息技术",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "深桑达A拟投资数字广东公司；凯莱英子公司签27.2亿元供货大单",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "凯莱英子公司签订约27.2亿元订单 恒瑞多款新药获批临床",
            "features": {
                "keywords": [
                    "凯莱英",
                    "子公司",
                    "订单",
                    "27.2亿元",
                    "恒瑞",
                    "新药",
                    "获批临床"
                ],
                "sentiment_score": 0.88,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "凯莱英子公司签订约27.2亿元订单 恒瑞多款新药获批临床",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "凯莱英：签订日常经营重大合同",
            "features": {
                "keywords": [
                    "凯莱英",
                    "重大合同"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "凯莱英：签订日常经营重大合同",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "凯莱英：子公司签订约27.2亿元新一批供货合同",
            "features": {
                "keywords": [
                    "凯莱英",
                    "子公司",
                    "供货合同",
                    "27.2亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "凯莱英：子公司签订约27.2亿元新一批供货合同",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "医药行业周报：本周医药板块上涨1.69% 建议关注OMICRON新变异株及医药三大防疫板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "医药板块",
                    "上涨",
                    "1.69%",
                    "OMICRON",
                    "变异株",
                    "防疫板块"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：本周医药板块上涨1.69% 建议关注OMICRON新变异株及医药三大防疫板块",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]